Welcome to our dedicated page for Asahi Kaisei Adr news (Ticker: AHKSY), a resource for investors and traders seeking the latest updates and insights on Asahi Kaisei Adr stock.
Asahi Kasei reports developments across a diversified global business that includes healthcare, materials, electronic components, and hydrogen-related technologies. News commonly covers pharmaceutical pipeline expansion, specialty pharmaceutical acquisitions, antiviral and autoimmune-disease programs, and subsidiary activity involving Veloxis Pharmaceuticals, Asahi Kasei Therapeutics, and Asahi Kasei Pharma.
Company updates also include Asahi Kasei Microdevices' magnetic-sensor and photonic technology work, chlor-alkali electrolysis products such as electrolyzer cells, ion-exchange membranes, and electrodes, and Aqualyzer™ alkaline-water electrolyzer deployments for hydrogen production. Recurring themes include research collaborations, license agreements, clinical and regulatory disclosures, material agreements, capital-structure updates, and operating and financial results.
Asahi Kasei (OTC:AHKSY) agreed to acquire Aicuris for approximately €780 million (about $919 million) with closing expected in Q1 fiscal 2026, subject to customary conditions. The deal adds three anti-infective assets — Prevymis royalties, pritelivir (Phase III) and AIC468 (Phase I) — and targets synergy with transplant and nephrology franchises.
Asahi Kasei expects the acquisition to contribute positively to operating income from fiscal 2028 after amortization, and cites a strategy to reach ¥300 billion pharmaceutical net sales with an operating margin ≥15% by fiscal 2030.
Asahi Kasei Pharma (OTC:AHKSY) announced an exclusive global license agreement with Alchemedicine for novel preclinical lead compounds on February 3, 2026. The compounds, discovered via Alchemedicine’s HiSAP™ platform, target a single mechanism with potential for multiple autoimmune diseases.
The program is independent of a June 2022 deal and follows advancement of AK1960 to Phase I, reflecting deeper collaboration and a push toward Asahi Kasei Group’s $3 billion pharma sales goal by 2030.
Asahi Kasei Microdevices (OTC: AHKSY) announced that its 1983 commercialization of thin-film Hall elements has been designated an IEEE Milestone on February 19, 2026.
The announcement highlights AKM innovations—InSb thin-film placement and a three-layer electrode enabling gold wire bonding—and notes over 50 billion Hall sensor units shipped globally and broad adoption across consumer electronics, brushless motors, HVAC efficiency, smartphones, and EV systems.
Asahi Kasei Pharma (OTC:AHKSY) and Alchemedicine announced that the ETA receptor antagonist AK1960 has entered a Phase I clinical study after successful preclinical work. AK1960 showed potent, selective ETA inhibition and efficacy in animal kidney disease models; development leverages an exclusive 2022 license and partners Calliditas and Veloxis.
The program is presently conducting preclinical and Phase I work in Japan with a global commercialization intent.
Asahi Kasei (OTC: AHKSY) announced a new PFAS-free polyamide (PA66) engineered for low-friction, high-load sliding applications. The material delivers stable performance in dry, high-temperature, and high-load conditions and is offered in unreinforced and reinforced grades with customizable properties via processing control technology.
Target uses include gears, chain guides, and other sliding components where oil or grease cannot be used; tailored formulations adjust filler content, stiffness, heat resistance, and wet-condition behavior to aid PFAS phase-out.
Asahi Kasei (AHKSY), Mitsui Chemicals, and Mitsubishi Chemical signed a basic agreement to form a joint operating entity to decarbonize and optimize two ethylene facilities in western Japan.
The plan uses METI’s Fiscal 2025 HtA Support Program, targets ¥21.2 billion total investment (maximum ¥10.4 billion subsidy), aims to consolidate AMEC operations into OPC by fiscal 2030, install a Revolefin™ bioethanol-to-ethylene/propylene pilot at Mizushima, target commercial decarbonized production in fiscal 2034, and expects a structural 506,000 t-CO2/year reduction.
Senseair (AHKSY) launched the S12 CO2, a next-generation NDIR CO2 sensor aimed at demand-controlled ventilation and battery-powered IAQ monitors. The S12 is ~75% smaller in volume than predecessors, measures 18 mm × 15 mm × 7 mm, supports SMD reflow mounting, and has a range of 400–10,000 ppm with accuracy of ±(30 ppm + 3% of reading). Samples are being distributed and mass production is planned in 2026. The sensor is positioned for DCV, BEMS, HVAC, and residential AC applications and claims compliance with ANSI/ASHRAE 62.1-2022 Addendum d, RESET Grade B, and WELL v2.
Asahi Kasei (AHKSY) announced that ZOLL Medical launched the next-generation LifeVest wearable cardioverter defibrillator (WCD) in the U.S. and completed the U.S. rollout of an upgraded, more comfortable LifeVest garment on January 8, 2026. The release cites >140,000 patients in peer-reviewed publications and >1 million lives protected, highlights AI-enhanced arrhythmia detection that reduced false alarms to a median of zero at 90 days, and describes garment improvements and size range (26"–56"). Asahi Kasei targets operating income of ¥55.0 billion in fiscal 2027 for its Critical Care priority, positioning ZOLL to pursue clinical adoption, market expansion, recurring revenue, and durable profitability.
Asahi Kasei Pharma (OTC: AHKSY) will relocate its global R&D hub from Ohito, Shizuoka to Shonan Health Innovation Park (Shonan iPark) in January 2027.
The move aims to strengthen global R&D for pharmaceuticals, accelerate open innovation with external partners, access a life-science ecosystem including AI/digital health and academia, and attract R&D talent via shared labs and state-of-the-art equipment. The company intends to focus on priority disease areas (autoimmune, severe infectious, transplantation, renal) and align relocation with its medium-term plan prioritizing pharmaceuticals and ongoing M&A.
Asahi Kasei Microdevices (AHKSY) and Aizip partnered to demo AI-enhanced sensing for health and wearables at CES 2026. AKM supplies millimeter-wave radar for real-time, non-wearable swallowing detection and an AK05611-based wristband for EMG gesture recognition; Aizip provides lightweight on-device AI that converts radar and EMG signals into clinical-grade insights locally and in real time. The swallowing demo targets aspiration-risk detection in older adults without cloud latency; the gesture demo maps forearm EMG to commands like open/close/tap. Both solutions emphasize privacy, low power, and immediate alerts to caregivers.